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Abstract
Background: Adiponectin is an adipose tissue secreted protein known for its insulin sensitising and anti-
atherogenic actions. To this date two adiponectin receptors have been discovered, adiponectin receptor 1
(ADIPOR1) and adiponectin receptor 2 (ADIPOR2). The aim of this study was to investigate the association of
ADIPOR2 gene variations with coronary artery disease (CAD).
Methods: Eight common single nucleotide polymorphisms (SNPs) spanning the entire ADIPOR2 locus were chosen
to perform association studies with anthropometric and metabolic parameters in a Greek population. They were
classified as either CAD (stenosis >50% in at least one main vessel) or non-CAD individuals in accordance with
coronary angiography data.
Genotyping was performed using a microsphere-based suspension array and the Allele Specific Primer Extension
(ASPE) method. Expression of ADIPOR2 protein and mRNA in circulating CD14
+ monocytes were determined using
flow cytometry and real time Polymerase Chain Reaction assays respectively.
Results: There was a significant difference in the distribution of genotypes of polymorphism rs767870 of ADIPOR2
between CAD and non-CAD individuals (p = 0.017). Furthermore, heterozygotes of the rs767870 polymorphism had
significantly lower Flow Mediated Dilatation (FMD) values, higher values of Intima-Media Thickness (IMT) and
increased ADIPOR2 protein levels in peripheral monocytes, compared to homozygotes of the minor allele after
adjustment for age, sex, waist to hip ratio and HOMA.
Conclusions: Our findings suggest that variants of ADIPOR2 could be a determinant for atherosclerosis
independent of insulin resistance status, possibly by affecting ADIPOR2 protein levels.
Background
Adiponectin is a protein secreted from adipocytes
released in the circulation of human healthy subjects at
relatively high levels [1-4]. Plasma adiponectin levels
have been reported as decreased in states of obesity,
type 2 diabetes and coronary artery disease [5-8]. Adipo-
nectin exerts its insulin-sensitising effects in the liver by
suppressing gluconeogenesis and in the skeletal muscle
by enhancing fatty acid oxidation [9]. Furthermore, adi-
ponectin exhibits anti-inflammatory and atheroprotec-
tive actions in various tissues by suppressing the
expression of vascular adhesion molecules and scaven-
ger receptors, reducing the expression of the inflamma-
tory cytokine TNF-a, raising NO production and
suppressing the proliferation and migration of smooth
muscle cells [10-14].
To this date, two receptors have been identified that
mediate adiponectin’s actions in fatty-acid oxidation and
glucose uptake, namely ADIPOR1 and ADIPOR2 [15].
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most tissues, albeit at different levels, and studies aimed
at their mRNA and protein expression levels in various
insulin resistant states have produced inconclusive
results [16-18]. It has been reported that the expression
of these receptors is either induced or reduced in adi-
pose and muscle tissues from obese and insulin resistant
subjects [19,20]. Furthermore, it was recently shown
that monocytes from overweight and obese individuals
with type 2 diabetes compared to normal-weight con-
trols have an impaired expression of adiponectin recep-
tors [21].
ADIPOR2 is a cell-surface receptor abundantly
expressed in skeletal muscle and liver, serving as a
receptor for both globular and full-length adiponectin.
Its protein expression has been demonstrated to be
either up-regulated in adipose tissue from insulin resis-
tant women with polycystic ovarian syndrome, or down-
regulated in monocytes from overweight/obese patients
with type 2 diabetes [19,21]. Similarly, its mRNA expres-
sion in skeletal muscle and adipose tissues from obese,
insulin resistant or type 2 diabetic patients follows the
same inconclusive results [17,18]. The ADIPOR2 gene is
located on chromosome 12p13.33, consisting of eight
exons. Single nucleotide polymorphisms (SNPs) of the
ADIPOR2 have been associated with either insulin resis-
tance or hepatic fat accumulation in various populations
[22-29], albeit not in all studies [30-33]. Nevertheless,
the role of genetic variants of ADIPOR2 in coronary
artery disease has not been studied yet.
In this study, we investigated the association between
eight common single nucleotide polymorphisms of the
ADIPOR2 gene with the presence of coronary artery dis-
ease and its protein expression from human peripheral
monocytes from the same individuals.
Methods
Subjects
Our study analysis consisted of 68 patients from the
Greek population with cardiovascular risk factors, who
were screened for the existence of chronic stable CAD.
All individuals underwent elective coronary angiography.
Case subjects (n = 40) were patients who had angio-
graphic evidence of stenosis > 50% in at least one major
coronary artery (CAD). Control subjects (n = 28) were
people without coronary stenosis at angiography (non-
CAD). Subjects with acute myocardial infarction, sys-
temic inflammatory diseases, malignancies, renal failure
(creatinin > 1.5 mg/dl), heart failure and severe obesity
with body mass index (BMI) > 35 were excluded from
our study.
All patients gave their written informed consent and
the study protocol was approved by the Scientific and
Ethics Committee of Attikon University General
Hospital. All patients were of a stable weight and had
been on a normal isocaloric diet with normal physical
activity during the previous four months. None of the
patients were taking thiazolidinedione medication. Waist
and hip circumferences were measured and the waist to
hip ratio (WHR) was calculated. BMI was calculated as
the ratio of weight (Kg) to height (m
2). All patients were
subjected to Intima-Media Thickness (IMT) assessment
in common carotids and in carotid bulbs as an index of
atherosclerosis, using B-mode ultrasound imaging (Vivid
7 General Electric Horten, Norway), as previously
described [34] and Flow Mediated Dilatation (FMD)
assessment of the brachial artery as an index of
endothelial dysfunction [35].
The coronary angiography was followed by a 2-hour
oral glucose tolerance test (OGTT) two weeks later.
Insulin resistance status in the fasting state was calcu-
lated by the homeostasis model assessment index
(HOMA) [36], whilst post-glucose insulin sensitivity was
calculated by the Matsuda index [37]. Fasting blood was
drawn at the beginning of the OGTT and plasma was
kept at -80°C for measurement of adiponectin levels.
Fasting triglycerides, as well as total and high-density
lipoprotein (HDL) cholesterol were determined by an
ILAB Analyser (Instrumentation Laboratory SpA, Italy).
Plasma glucose levels at fasting and during the OGTT
were analysed on a Falcor 300 chemical analyser
(Menarini diagnostics, Italy) and their corresponding
insulin levels were measured by IRMA (INSI-CTK, Dia
Sorin, Italy).
Genomic DNA isolation
Fasted blood was collected from all individuals and
genomic DNA was extracted from the buffy coat
according to the manufacturer’s instructions (Flexigene
DNA Kit, Qiagen, Chatsworth, CA, USA). The quality
and the integrity of the DNA samples was determined
by standard ethidium-bromide agarose gels and quantifi-
cation was performed spectrophotometrically (UV/VIS
Spectrometer Lambda Bio10, Perkin Elmer, USA). The
following common single nucleotide polymorphisms
were examined lying either in the promoter [rs10773980
C/T and rs1029629 C/T], the intron 5 [rs767870 A/G],
the exon 6 [rs16928751 G/A], the exon 7 [rs9805042
C/T and I290I C/A] and the exon 8 [rs12342 C/T and
rs1044771 C/T] of ADIPOR2 (Fig. 1).
Genotyping of ADIPOR2 polymorphisms using the Allele
Specific Primer Extension (ASPE)
The Allele Specific Primer Extension assay and xMAP
technology were used to genotype our samples. This
technique is a solution-based sequence-specific enzy-
matic reaction that determines the target SNPs. It
i n v o l v e st h ei n c o r p o r a t i o no fas p e c i f i cc a p t u r e
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(ASPE) that carries the major or the minor nucleotide
of the SNP at its 3’ -end [38,39]. Therefore, two ASPE
primers are needed for every SNP in order to resolve
each possible allele pair. ASPE primers also carry a tag-
sequence which hybridises to a complementary sequence
called anti-tag, in the surface of the polystyrene micro-
spheres (xMAP microspheres), which are internally dyed
with fluorophores.
Various PCR products encompassing the SNPs of
interest, ranging in size from 353 to 1180 bp, were gen-
erated through standard PCR reactions from human
genomic DNA, using Platinum Taq Polymerase (Invitro-
gen, Carlsbad, CA, USA) in a GeneAmp 9600 thermocy-
cler (Perkin Elmer Inc, Massachusetts, USA). An aliquot
from the PCR reactions was run on 1.5% agarose gels
and visualised with ethidium bromide staining. Product
lengths were estimated using a standard molecular
weight marker (FX174-HaeIII digest, NEB, UK) (Fig 2A
and 2B) and subsequently the PCR products were trea-
ted with exo-SAP mix (2:1) (Exonuclease I:Shrimp Alka-
line Phosphatase, USB Europ eG m b H ,G e r m a n y )a t3 7 °
C for 30 minutes in order to remove unconsumed
dNTPs and primers remaining in the mixture, followed
by inactivation at 80°C for 15 minutes. Consequently
the treated PCR products were combined with ASPE
primers and extension took place with the use of biotin-
14-dCTP and Platinum Tsp DNA Polymerase (Invitro-
gen, Carlsbad, CA, USA). Extension occurs only if the 3’
nucleotide of the ASPE primer is complementary to the
template DNA. The conditions for the ASPE reaction
were as follows: denaturation at 96°C for 2 minutes,
amplification for 40 cycles at 95°C for 30 seconds, 54°C
for 30 seconds and 74°C for 60 seconds, followed by
one cycle at 4°C. The subsequent hybridisation of the
anti-tag microsphere to the biotinilated ASPE-tag PCR
product took place at 37°C for 60 minutes, after a short
denaturation cycle at 95°C for 90 seconds.
Finally, a fluorescent-labelled reporter molecule
(Streptavidin-R-phycoerythrin, 1 mg/ml, Molecular
Probes, Invitrogen, Carlsbad, CA, USA) binds to the bio-
tinilated hybrid ASPE microsphere product. This cou-
pling of the reporter molecule quantifies the
biomolecular interaction that occurs at the microsphere
surface. The reaction can finally be analysed on a Lumi-
nex 200 instrument (Luminex Corp, TX, USA). Preci-
sion fluidics aligns the microspheres in single file and
passes them through the lasers, one at a time. One laser
excites the reporter molecule bound to the microsphere
surface and the second laser excites the microsphere
fluorophores. Reactions are measured with fluorescent
intensity and reported in real time. The fluorescent sig-
nals generated for each microsphere bead population
were used to assess the genotype in each sample. The
median fluorescent intensities (MFI) were used to calcu-
late allelic rations for each allele as follows:
Allelic Ratio
MFI allele 
MFI allele  MFI allele 


a
aa
1
12 ()
To be homozygous for a particular allele, the allelic
ratio must be at least 0.75. For heterozygous samples
each allele must have a ratio between 0.25 and 0.75. An
allele with a ratio of 0.25 or less is considered negative i.
e. not present. Representative samples results are shown
in figure 3A.
Determination of ADIPOR2 mRNA and protein expression
Peripheral monocytes were isolated from mononuclear
cells using a Magnetic Cell-Sorting technique and the
CD14 Human MicroBeads (Miltenyi Biotec, Gladbach,
Germany). The purity of the magnetically isolated
CD14
+ monocytes was determined after staining the
cells with a CD14 PE-CD45 FITC antibody (BD Bios-
ciences, San Jose, CA, USA).
Total RNA was extracted from CD14
+ monocytes
using the Tripure Isolation Reagent (Roche Diagnostics
GmbH, Mannheim, Germany). Reverse transcription of
1 μg of total RNA was performed in all samples with
the Transcriptor First Strand cDNA Synthesis Kit using
Figure 1 Schematic representation of the ADIPOR2 gene. The polymorphisms studied are represented by vertical arrows. Empty boxes
denote exons and black boxes denote sequences translated into protein. +1 represents the ATG translation start site.
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turer’s instructions (Roche Diagnostics GmbH, Man-
nheim, Germany).
A quantitative real-time PCR using fluorescent-labelled
hybridisation probes was developed for detecting relative
ADIPOR2 mRNA levels, in human CD14
+ monocytes,
using the calibrator-normalised standard curve and the
LightCycler Relative Quantification 1.0.1 Software, in a
spectrofluorometric thermal cycler (LightCycler, ROCHE,
Manheim, Germany), as previously described [40]. The
human housekeeping gene of b- a c t i nw a su s e da ss t a n -
dard for normalisation. Hybridisation specific primers
and fluorescent-labelled hybridisation specific probes for
the genes were designed and manufactured by the TIM-
MOLBIOL (Berlin, Germany). Hybridisation primers and
probes for the target and reference genes were as follows:
Primers were chosen to lie between exons whenever
possible and the analysis was performed with the
programme OLIGO 6.0 (Molecular Biology Insights,
Cascade, USA).
For quantifying the relative expression levels of ADI-
POR2 mRNA in the various samples, we ran the target
(AdipoR2) and the reference (b-actin) gene of each sam-
ple along with the calibrator cDNA, using the Second
Derivative Maximum Method with the Arithmetic base-
line adjustment for the determination of the various
crossing points (Fig 3B). Samples were run in duplicates
or triplicates and results are expressed in arbitrary units.
Surface adiponectin receptor ADIPOR2 was deter-
mined after staining the isolated cells (’buffy’coat) with a
suitable antibody (Alpha Diagnostic International, San
Antonio, USA). Since the antibody was not fluoro-
chrome conjugated, it was labelled with the Zenon™
Alexa Fluor® 488 Rabbit IgG labelling kit (Invitrogen,
Carlsbad, CA, USA). Cells were incubated for 30 min-
utes with Alexa Fluor® 488-conjugated immunoglobulin
in a ratio 1 × 10
6cells μg
-1 of immunoglobulin under
mild constant shaking. The monocyte fraction was
simultaneously stained with anti-CD14-PE monoclonal
antibody (BD Biosciences, San Jose, CA, USA). The
Figure 2 Representative PCR reactions showing the PCR specific bands for all polymorphisms studied of the ADIPOR2 (A). Detection of
the PCR specific bands for polymorphism rs767870, lanes 2 and 3 show the PCR specific bands amplified from human genomic DNA from two
CAD individuals, while lanes 4 and 5 show the PCR bands amplified from human genomic DNA from two non-CAD individuals. (B) Detection of
the PCR specific bands for polymorphisms: rs10773980 (lane 1), rs1029629 (lane 2), rs16928751 (lane 3), I290I (lane 4), rs9805042 (lane 5), rs12342
(lane 6) and rs1044771 (lane 7). Arrows show the base pair size of the various PCR products. M: FX174-HaeIII digest
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ing cells with isotype control suitable for each antisera
and the blockage of Fc-receptors prior to staining.
Two-colour flow cytometric analysis was performed
on a BD FACSCalibur 4 colour flow cytometer (BD
Biosciences) equipped with two air-cooled lasers: a 15
mW Argon laser (488 nm) and a Red Diode laser (632
nm). Data acquisition and analysis were performed
using the BD CELL Quest Pro software (BD Bio-
sciences). Results are expressed in mean fluorescence
intensity arbitrary units (MFI AU).
Adiponectin plasma levels
Circulating levels of adiponectin were measured in the
plasma of all subjects, using a high sensitivity multiplex
assay (xMAP technology) and fluorescent-labelled
Figure 3 Diagrammatic representation of: (A) the genotyping results for rs767870 polymorphism of ADIPOR2 using the Allele Specific
Primer Extension assay and the xMAP technology and (B) the detection of the relative ADIPOR2 mRNA levels using the real-time PCR
assay. A. Bars represent the two alleles of the rs767870 polymorphism (G allele: blue bars, A allele: orange bars). The results show three different
individuals: on the left, an individual homozygote for the A allele (AA genotype), in the centre, a heterozygote carrying both alleles (AG
genotype) and on the right side, a homozygote for the G allele (GG genotype). B. A quantification analysis screen from a typical real-time PCR
run, showing the fluorescence acquisition for the ADIPOR2 (green and black curves) and the b-actin (red and pink curves) mRNA levels on the y
axis and the number of cycles on the x axis. Results are shown for two different individuals, a CAD (green and red curves) and a non-CAD
individual (black and pink curves).
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pore Corp., MA, USA), in a LUMINEX 200 instrument
(Luminex Corp, TX, USA). Sensitivity of the assay was
56.0 pg/ml, intra-assay and inter-assay coefficients of
variation were 9.2% and 15.9%, respectively. All samples
were diluted 1:100 and measured in duplicate. Samples
that could not be detected were measured again using a
higher dilution.
Statistical analysis
Statistical analysis was performed using the SPSS version
14.0 software (Chicago IL, USA). Deviation of SNPs
from the Hardy-Weinberg equilibrium was performed
using the chi-square test and the Hardy-Weinberg equi-
librium calculator [41]. If genotype frequencies for a
particular SNP differ from those expected under equili-
brium, the Hardy-Weinberg principle is being violated
and is therefore not safe to try to associate this SNP
with coronary artery disease. Distribution of alleles was
compared using the c
2 and the level of significance
adopted was p < 0.05. The whole population odds ratio
associated with genotypes was calculated by binary logis-
tic regression analysis. Normal distribution was tested
with the Kolmogorov-Smirnov test and logistic
transformations of variances to achieve normal distribu-
tion were used when needed. The differences in various
variables between genotypes were evaluated with the
univariate ANOVA, adjusted for age, sex, BMI and
HOMA. Kruskal-Wallis test was also used when homo-
geneity of variances were not met. Non-parametric
Mann-Whitney and 2-independent samples t-tests were
used accordingly for analysis. Data are expressed as
means ± SEM.
Results
General characteristics of the subjects
The clinical and metabolic characteristics of the popula-
tion studied (CAD and non-CAD) are shown in table 1.
There were no significant differences between the two
groups regarding age, weight, BMI, fasting and two-hour
glucose and insulin levels, insulin resistance indices
(HOMA and Matsuda), lipid levels (total cholesterol,
LDL, HDL), systolic and diastolic blood pressure,
endothelial dysfunction (FMD) and the circulating adi-
ponectin (Table 1). However, CAD patients had higher
WHR and IMT values compared to control subjects
(Table 1). Furthermore, CAD subjects had higher ADI-
POR2 mRNA levels, while they did not differ in
Table 1 Anthropometric and metabolic characteristics of the people studied
NonCAD (n = 28) CAD (n = 40) p
Anthropometric characteristics
Age (years) 56.61 ± 1.47 59.80 ± 1.34 NS
Body weight (kg) 80.28 ± 2.09 83.69 ± 1.51 NS
BMI (Kg/m
2) 28.12 ± 0.51 28.53 ± 0.49 NS
WHR 0.93 ± 0.01 0.99 ± 0.01 0.001
Metabolic characteristics & Indices
Fasting plasma glucose (mg/dl) 106.76 ± 6.19 113.29 ± 4.5 NS
Two-hour plasma glucose (mg/dl) 162.81 ± 15.30 199.35 ± 12.79 NS
Fasting plasma insulin (μU/ml) 14.39 ± 1.84 13.79 ± 1.15 NS
Two-hour plasma insulin (μU/ml) 100.09 ± 12.74 135.41 ± 22.53 NS
HOMA index 3.80 ± 0.58 4.68 ± 0.69 NS
Matsuda index 2.84 ± 0.24 2.68 ± 0.25 NS
Total cholesterol (mg/dl) 193.26 ± 8.55 183.32 ± 5.85 NS
LDL (mg/dl) 128.00 ± 8.68 122.71 ± 4.88 NS
HDL (mg/dl) 49.29 ± 2.62 45.97 ± 1.97 NS
Trigycerides (mg/dl) 114.46 ± 10.04 133.39 ± 10.95 NS
Systolic blood pressure (mm Hg) 122.32 ± 2.94 128.06 ± 2.57 NS
Diastolic blood pressure (mm Hg) 76.25 ± 1.76 78.89 ± 1.34 NS
IMT(mm) 0.83 ± 0.05 1.09 ± 0.05 0.001
IMT bulb (mm) 1.13 ± 0.15 1.45 ± 0.08 NS
FMD (%) 8.59 ± 1.28 7.01 ± 0.81 NS
Adiponectin (μg/ml) 13.01 ± 1.09 13.18 ± 1.30 NS
ADIPOR2 mRNA (AU) 0.81 ± 0.06 1.2 ± 0.16 0.035
ADIPOR2 protein (MFI) 82.97 ± 9.83 65.60 ± 4.68 NS
Data are given as means ± SEM. BMI: Body Mass Index, LDL: Low Density Lipoprotein, HDL: High Density Lipoprotein, IMT: Intima Media Thickness; FMD: Flow
Mediated Dilatation.
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+monocytes, compared to controls.
Allele frequencies of ADIPOR2 polymorphisms
The allele frequencies of the investigated polymorphisms
of the ADIPOR2 are shown in table 2. Only rs767870
and rs1044771 polymorphisms were found to be in
Hardy-Weinberg equilibrium, (p < 0.05, c
2 < 3.83). Thus
we excluded from further analysis, any polymorphism
that deviated from Hardy-Weinberg equilibrium.
Association of rs767870 SNP with coronary artery disease
We subsequently investigated the distribution of geno-
types for the rs767870 and rs1044771 polymorphisms
between the two populations and their possible associa-
tion with coronary artery disease (Table 3). There was a
significant difference in the distribution of alleles of
rs767870 polymorphism of ADIPOR2 between CAD and
non-CAD individuals (p = 0.017).
No significant difference was found in the distribution
of alleles for the rs1044771 polymorphism of ADIPOR2
between the two groups (Table 3).
Using binary logistic regression analysis, the risk for
CAD for AG heterozygotes of the rs767870 poly-
morphism was 50% higher compared to AA homozy-
gotes of the same polymorphism, although not to a
significant degree (OR = 1.543 and 95% CI: 0.465-
5.120) (Table 3). Furthermore, the marker rs767870 of
ADIPOR2 was most significantly associated with waist
circumference, IMT and FMD measurements in all
individuals (Table 4). To be more specific, AA homo-
zygotes and AG heterozygotes of the rs767870 had
significantly higher IMTbulb and lower FMD values
compared to GG homozygotes (1.62 ± 0.21 mm and
5.09 ± 0.76% vs 1.26 ± 0.07 mm and 7.62 ± 0.74%,
p = 0.025 and p = 0.002, adjusted for age, sex, BMI,
WHR and HOMA, respectively) (Table 4 and Fig.4A
and 4B).
We then investigated the possibility that the associa-
tion of rs767870 polymorphism with markers of
endothelial dysfunction and atherosclerosis may be
mediated through an effect on gene expression. In per-
ipheral CD14
+ monocytes, carriers of the major A allele
(homozygotes and heterozygotes) of rs767870 poly-
morphism had higher levels of ADIPOR2 protein
expression compared to homozygotes of the minor allele
(69.17 ± 4.80 MFI and 92.03 ± 14.41 MFI vs 45.20 ±
7.70 MFI, p = 0.008, after adjustment for age, sex, WHR
and HOMA) (Table 4 and Fig. 4C).
Discussion
We have demonstrated for the first time that a sequence
variant in the intron 5 of the ADIPOR2, rs767870
among the eight studied, is associated with cardiovascu-
lar disease in our population of Greek individuals.
Furthermore, genotypes from this variant are associated
with higher IMT and lower FMD values in the same
population, while they exhibit higher ADIPOR2 protein
levels in circulating monocytes.
ADIPOR1 and ADIPOR2 are considered promising
genes for type 2 diabetes, the metabolic syndrome and
its complications, such as cardiovascular disease [42].
The ADIPOR2 is located on chromosome 12p13.31 and
comprises of eight exons. Various studies have asso-
ciated genetic variants of the ADIPOR2 locus with insu-
lin resistance and the traits of the metabolic syndrome
[21-29], whilst several others have failed to confirm this
[30-33]. In particular, ADIPOR2 variants have been
strongly associated with type 2 diabetes in the Old
Amish Order and in a Chinese population [22,24].
Table 2 Allele frequencies of ADIPOR2 gene
polymorphisms in the Greek population studied
Polymorphism Major/minor allele allele frequencies
rs10773980 C/T C/T C: 0.507, T: 0.492
rs1029629 C/T C/T C: 0.662, T: 0.338
rs767870 A/G A/G A: 0.801, G: 0.199
rs16928751 G/A G/A G: 0.853, A: 0.147
I290I C/A C/A C: 0.889, A: 0.111
rs9805042 C/T C/T C: 0.632, T: 0.368
rs12342 C/T C/T C: 0.507, T: 0.493
rs1044771 C/T C/T C: 0.463, T: 0.537
Table 3 Associations between polymorphisms of ADIPOR2 and the risk of coronary artery disease
SNPs Major/minor allele genotype CAD (%) Non CAD (%) p
a OR (95% CI)
p
b
rs767870 A/G AA 70 64.2 0.017 0.479 (0.465-5.120)
AG 30.0 17.9 0.999
GG 0.0 17.9
rs1044771 C/T CC 22.5 10.7 0.510 0.557 (0.317-8.454)
CT 50.0 67.9 0.355
TT 27.5 21.4
Genotype distributions are shown as per cent (%).
a p-value according to chi-square test,
b p-value according to binary logistic regression analysis, OR: Odds ratio,
95% confidence interval (CI).
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ciated with decreased triglyceride levels in Mexicans
with insulin resistance and in Germans with metabolic
syndrome [27,28].
We chose to study ADIPOR2 because the effects of
ADIPOR2 gene variants in cardiovascular disease have
not yet been examined. It has been demonstrated that at
least for ADIPOR1, sequence variants in its 3’-region,
are significant determinants of cardiovascular risk in
type 2 diabetes [43]. Moreover in the same study, the
authors have found that haplotypes of the above variants
are also associated with lower ADIPOR1 mRNA levels in
mononuclear cells and adipose tissue biopsies.
In our study, we have demonstrated that carriers of
the major allele of the rs767870 polymorphism of the
ADIPOR2 are associated with 78% higher ADIPOR2
protein expression in circulating monocytes, compared
to homozygotes of the minor allele, independent of age,
gender, obesity measures and insulin resistance. Further-
more, these same individuals compared to minor allele
homozygotes, have 56% and 83% higher IMT values at
both common carotids and carotid bulbs respectively,
while at the same time they show 67% lower FMD
values, independent of age, gender, obesity measures
and insulin resistance. It has been shown that the
reduction of FMD increases the risk of coronary artery
disease [44], whilst increments in the IMT measure-
ments are associated with atherosclerosis progression
[45]. In line with this, our findings could suggest that
individuals carrying the A allele of the rs767870
polymorphism of ADIPOR2 are prone to atherosclero-
tic events that could possibly be mediated via increased
ADIPOR2 expression.
The mechanisms through which variations in the ADI-
POR2 could influence atherosclerosis and cardiovascular
disease are only hypothetical at the moment. The
rs767870 polymorphism lies inside intron 5 of the ADI-
POR2 locus and is not translated to amino acid. Never-
theless, such silent SNP could influence adiponectin
receptor concentrations with unknown mechanisms.
Our findings that genotypes of the rs767870 variant of
the ADIPOR2 are associated with protein expression in
circulating monocytes (the precursors of foam cells that
populate atherosclerotic lesions), makes the hypothesis
that ADIPOR2 could affect atherosclerosis through its
protein expression attractive.
Monocytes play a pivotal role in inflammation and
atherosclerosis. These are the sites in which adiponectin
exerts its anti-inflammatory and anti-atherogenic effects,
mainly by inhibiting the secretion of inflammatory cyto-
kines from monocyte-derived macrophages, by prevent-
ing monocyte adhesion to endothelial cells and by
suppressing macrophage-to-foam cell transformation
[9,10]. Whilst initially our findings that associate
increased atherosclerosis with higher ADIPOR2 expres-
sion in monocytes seem paradoxical, one could consider
a compensatory up-regulation mechanism of ADIPOR2
expression to exist in individuals with advanced athero-
sclerosis in order to counteract their adverse metabolic
and cardiovascular outcomes. Furthermore, upregulation
Table 4 Anthropometric and metabolic characteristics of the study population divided according to the genotypes of
rs767870 of the ADIPOR2
rs767870 A/A A/G G/G p p
SEX (male/female) 40/6 15/2 3/2 0.25
a
Age (years) 58.50 ± 1.29 59.53 ± 1.88 54.80 ± 2.48 0.54
Weight (Kg) 81.73 ± 1.43 86.25 ± 2.74 75.10 ± 3.58 0.078
Height (cm) 1.70 ± 0.01 1.71 ± 0.01 1.63 ± 0.01 0.056
BMI (Kg/m
2) 27.97 ± 0.40 29.46 ± 0.82 28.18 ± 1.09 0.198
Waist circumference (cm) 98.23 ± 1.39 103.37 ± 2.55 91.6 ± 3.88 0.040 0.067
b
Hip circumference (cm) 101.52 ± 1.01 104.75 ± 2.34 100.20 ± 2.99 0.278
WHR 0.96 ± 0.01 0.99 ± 0.01 0.91 ± 0.03 0.128
IMT (mm) 1.01 ± 0.05 1.02 ± 0.09 0.65 ± 0.09 0.028
c 0.053
d
IMT bulb (mm) 1.26 ± 0.07 1.62 ± 0.21 0.78 ± 0.21 0.019 0.025
e
FMD (%) 7.62 ± 0.74 5.09 ± 0.76 16.97 ± 4.54 0.0001 0.002
e
HOMA 4.02 ± 0.63 4.42 ± 0.47 5.09 ± 2.81 0.887
Matsuda 2.87 ± 0.24 2.31 ± 0.23 3.12 ± 0.72 0.345
Adiponectin (μg/ml) 12.42 ± 0.73 15.82 ± 2.86 10.19 ± 1.24 0.168
AdipoR2 mRNA (AU) 1.02 ± 0.12 1.16 ± 0.23 0.83 ± 0.10 0.732
AdipoR2 protein (MFI) 69.17 ± 4.80 92.03 ± 14.41 45.20 ± 7.70 0.039 0.008
f
Data are means ± SEM,
achi square test,
bANOVA for comparison among all three genotype groups adjusted for age and sex,
cANOVA for comparison among all
three genotype groups after logarithmic transformation of values,
dANOVA for comparison among all three genotype groups adjusted for age and BMI, after
logarithmic transformation,
eANOVA for comparison among all three genotype groups adjusted for age, sex, BMI, WHR and HOMA,
fANOVA for comparison
among all three genotype groups adjusted for age, sex, WHR and HOMA.
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Page 8 of 11Figure 4 Genotype effects of the SNP 767870 of ADIPOR2 on the: (A) IMTbulb measurement, (B) FMD measurement and (C) ADIPOR2
protein levels from CD14+ monocytes. Data are means ± SEM. Differences between genotype groups were analysed by ANOVA adjusted for
age, sex, BMI, WHR and HOMA (A and B, p = 0.04 and p = 0.002 respectively) and ANOVA adjusted for age, sex, WHR and HOMA (C, p = 0.05)
* p < 0.05 vs GG homozygotes §p < 0.05 vs AG heterozygotes.
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Page 9 of 11of adiponectin receptors, which might reflect an
increased need for adiponectin signalling has also been
demonstrated in the adipose tissue of women with poly-
cystic ovarian syndrome [19] and in the skeletal muscle
of insulin resistant and type 2 diabetic subjects [16].
It is of particular interest that three different studies
have identified the rs767870 variant of the ADIPOR2,a s
being associated either with triglyceride levels and fat
accumulation or as a determinant of type 2 diabetes.
More specifically, in a genetic association analysis in the
French population, rs767870 was the only genetic mar-
ker associated with type 2 diabetes of the 12 ADIPOR2
SNPs studied [23]. The association remained significant
in a meta-analysis study of three case-control studies. It
was also the only one associated with liver fat content
in the Finnish population [20]. Moreover, Richardson et
al have demonstrated that homozygotes for the minor
allele of rs767870 variant, were associated with lower
triglyceride levels in insulin resistant Mexicans [28]. By
contrast, this SNP was not associated with insulin resis-
tance in another study in the German population [30].
However, our study findings should be interpreted
bearing in mind some limitations. The number of our
study subjects is generally regarded as small for genetic
association studies. Nevertheless we found no major dif-
ference in the allelic frequencies of the rs767870 poly-
morphism in our Greek population, with the allelic
frequencies in other European populations (HapMap-
CEU). Nevertheless our findings must be confirmed on
a larger sample and with other ethnicities.
Conclusions
Our data provides evidence for the first time that the
rs767870 variant of the ADIPOR2 could be a determi-
nant of endothelial disturbance and early atherosclero-
sis in the Greek population, independent of insulin
resistance, possibly through the elevated ADIPOR2
protein expression in circulating monocytes.
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